pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Obesity · news · pharmadog
← back to Obesity
News mentioning Obesity
737
stories
13d
This week in charts: 3 drug launches Wall Street is watching
biopharma dive
13d
Opinion: AI depends on medical records that don’t always tell the full truth about women
stat
13d
Recent Lisata prize Marea touts ‘exciting’ lipid disorder phase 2 win, mulls obesity potential
fiercebiotech
13d
AHA: Boehringer aims for 2027 survodutide submission after obesity drug passes cardio test
fiercebiotech
14d
Coveted metabolic gem Rhythm reportedly gets $10B offer from AstraZeneca
biospace
14d
Rezera revs up for $181M IPO to fund phase 3 trial of NLRP3 inhibitor
fiercebiotech
14d
MetaVia sees GLP-1 shed liver fat and body weight in phase 1, takes aim at specific liver disease
fiercebiotech
14d
AstraZeneca said to offer $10B to acquire Rhythm, analysts whisper of a bidding war
fiercebiotech
14d
A treatment revolution is underway in MASH
biospace
15d
Novo gets much-needed lift as Wegovy pill tops Wall Street forecasts
biopharma dive
15d
AbbVie bets up to $1.47B for Nxera’s discarded IBD program
biospace
15d
Amgen starts MariTide autoinjector study as pivotal readouts approach
biospace
15d
Biopharma likely to climb higher after ‘blue wave,’ analysts say
biopharma dive
15d
STAT+: Ultragenyx cuts staff after another study fails
stat
15d
With MFN now embedded in pharma, execs see little impact from Democrats’ blue wave
biospace
15d
Novo, Lilly battle for oral GLP-1 dominance with data tit for tat
biospace
15d
Pfizer eyes Europe first for Lyme vaccine as prevalence rises in US
biospace
15d
Novo won't launch CagriSema in Europe for 'a couple of years,' CFO says
endpoints
15d
Q3 earnings roll on, FDA pushes rare disease, uniQure’s Huntington’s therapy reaches review
biospace
15d
Opinion: I moved to Europe for free health care. I miss my patient portal
stat
15d
Novo’s CEO still looking for deals to ‘close some of the gaps,’ as misfires hit profits
fiercebiotech
16d
Pfizer, fresh to China’s obesity market, looks to Viagra model to compete
biospace
16d
STAT+: Who will get the first psychedelic approved?
stat
16d
Neurocrine defends Prader-Willi drug after another patient death
biospace
16d
Novartis puts $772M BioArctic deal on ice, skates away from brain-delivery alliance
biospace
16d
Pfizer flat in Q3 despite 32% growth for new and acquired products
biospace
16d
Rhythm doubles down on LG obesity license, raising payout to as much as $855M
fiercebiotech
16d
Opinion: What the 2024 electoral map reveals about America’s mortality divide
stat
16d
Pfizer pares back obesity pipeline, drops phase 2-stage lung disease candidate
fiercebiotech
17d
FDA peptide policy risks undermining drug development and patient safety
biospace
← prev
page 3 of 25
next →